1. Comparison of One-Year Outcome of Intravitreal Aflibercept with or without Photodynamic Therapy for Polypoidal Choroidal Vasculopathy.
- Author
-
Weng HY, Chen FT, Wang LU, Huang TL, Ho WT, Chang PY, Hsu YR, Chen YJ, and Wang JK
- Subjects
- Humans, Female, Male, Retrospective Studies, Aged, Middle Aged, Treatment Outcome, Choroid Diseases drug therapy, Choroid blood supply, Polypoidal Choroidal Vasculopathy, Receptors, Vascular Endothelial Growth Factor therapeutic use, Receptors, Vascular Endothelial Growth Factor administration & dosage, Recombinant Fusion Proteins therapeutic use, Recombinant Fusion Proteins administration & dosage, Photochemotherapy methods, Intravitreal Injections, Visual Acuity drug effects
- Abstract
Background and Objectives : Our study compared the visual and anatomical outcomes of polypoidal choroidal vasculopathy (PCV) patients receiving intravitreal aflibercept (IVA) with or without photodynamic therapy (PDT) over 12 months. Materials and Methods : This retrospective study was performed for 60 eyes from 60 patients with treatment-naïve PCV. Thirty eyes were treated using IVA monotherapy (IVA group), and thirty eyes were treated using a combination of IVA with PDT (IVA/PDT group). The baseline characteristics, treatment outcomes, and retreatment rates were compared between the two groups over a one-year follow-up period. Results : The best-corrected visual acuity (BCVA) was found to have improved significantly in the IVA/PDT group at every 3-month visit. However, no significant BCVA improvement was observed in the IVA group. A significantly lower retreatment rate and higher dry macula rate were found in the IVA/PDT group than that in the IVA group. In the entire population of the study, a better baseline vision and younger age were associated with better final visual outcomes. Retreatment was associated with poor baseline BCVA and IVA monotherapy. Conclusions : The combination of IVA and PDT may offer superior visual improvement and a higher dry macula rate compared to IVA monotherapy in the treatment of PCV patients while requiring fewer retreatments over 12 months.
- Published
- 2024
- Full Text
- View/download PDF